Functional and anatomical evaluation of the effect of nepafenac in prevention of macular edema after phacoemulsification in diabetic patients

Tharwat Mokbel, Sameh Saleh, Mona Abdelkader, Sherief E. El-khouly, Waleed Abou Samra, Mohamed Mamdouh

Mansoura Ophthalmic Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

Correspondence to: Sameh Saleh. Ophthalmology Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. yohaahmed12@yahoo.com

Received: 2018-04-30 Accepted: 2018-11-09

Abstract

• AIM: To evaluate the effect of prophylactic administration of nepafenac in prevention of macular edema occurring in diabetic patients after phacoemulsification and to investigate the correlation between optical coherence tomography (OCT) foveal thickness and multifocal electroretinogram (MF-ERG) parameters.

• METHODS: The study included two groups. Group 1 included 50 diabetic patients with senile cataract (50 eyes, 30 females, 20 males, aged 55±7y) received nepafenac 0.1% eye drop. Group 2 included another 50 diabetic patients with senile cataract (50 eyes, 22 female, 28 males, aged 53.8±8y) did not receive nepafenac. All patients were followed up for 3mo postoperatively. OCT and MF-ERG were done preoperative and at 1wk, 1, 2 and 3mo.

• RESULTS: The mean foveal thickness was statistically significantly lower in Group 1. Five eyes in Group 2 developed clinical cystoid macular oedema (CMO) (10%), and no patients in Group 1 developed central macular thickening more than 50 µm. There were insignificant differences in MF-ERG amplitudes and latencies between the two groups except in the five eyes that developed CMO, there statistically significant reduction of MF-ERG amplitude with increase in foveal thickness.

• CONCLUSION: Perioperative nepafenac reduces the incidence of CMO following uncomplicated phacoemulsification significantly. Nepafenac has no side effects.

• KEYWORDS: nepafenac; macular edema; cataract surgery; diabetes; optical coherence tomography; multifocal electroretinogram

DOI:10.18240/ijo.2019.03.06

INTRODUCTION

Macular oedema is common complication after phacoemulsification surgery in diabetic patients, even with uncomplicated cases[1]. Macular oedema is one of the main causes of unfavorable visual outcome after cataract surgery. Previous studies reported that incidence of clinical cystoid macular oedema (CMO) after phacoemulsification is up to 2.35%[2]. However, other, reported up to 9% angiographic CMO and increased foveal thickness measured by optical coherence tomography (OCT)[3]. Although, the mechanism of CMO is still controversial, the most acceptable is intraocular inflammation and prostaglandin release that break the blood-retinal barrier increasing permeability and passage of liquid to subfoveal space[4]. This is the cause of the use of nepafenac in treatment of CMO. Post-operative CMO is more commonly seen in patients with non-insulin dependent diabetes mellitus (NIDDM) than insulin dependent. Macular changes in diabetic patients are accelerated by cataract surgery[5]. Nepafenac is non-steroidal anti-inflammatory drug (NSAIDs) which decrease pro-inflammatory prostaglandin by their inhibitor effect on cyclooxygenase[6]. Nepafenac can penetrate corneal epithelium. Nepafenac is converted to active amfenac within the eye producing its anti-inflammatory effect[7]. Amfenac is a highly potent inhibitor of prostaglandin (PGs) production through inhibition of both Cox-1 and Cox-2, but can’t penetrate the corneal epithelium[8]. The aim of this study was to evaluate the effectiveness of nepafenac in prevention of CMO after phacoemulsification in diabetic patients, and to evaluate its toxicity on the retina.

SUBJECTS AND METHODS

Ethical Approval All subjects were carried out in accordance with the tenets of the Declaration of Helsinki (1989) of the World Medical Association. The study was approved by Mansoura International Review Board Ethics Committee. Each patient signed a written consent.
The study was done randomized. This study was carried out on patients attending the Out Patient Clinic of Mansoura Ophthalmic Center during the period from May 2015 to December 2017. The study included 100 eyes of 100 diabetic patients with senile cataract. They were divided into two groups. Group 1 included 50 eyes of 50 patients received perioperative nepafenac 0.1% and Group 2 included also 50 eyes of 50 patients (control group).

**Inclusion Criteria** Diabetic patients (without diabetic fundal changes) with senile immature cataract underwent phacoemulsification with posterior chamber intraocular lens (PC-IOL).

**Exclusion Criteria** Ten patients were excluded from the study. Any anterior segment pathology: as corneal opacities, pseudoxfoliation syndrome or dense cataract interfering with OCT imaging or multifocal electroretinogram (MF-ERG) fixation. Any posterior segment pathology: as, diabetic retinopathy (DR) previous retinal photocoagulation therapy, diabetic macular edema, history of uveitis. Any intraoperative or post-operative complications. Any medication may interfere with the assessment of the study outcome measures. Previous intraocular surgery or ocular trauma, hypersensitivity to NSAIDs.

All patients underwent complete ophthalmological examination, OCT, MF-ERG before phacoemulsification. Then, all patients were followed up 1d, 1wk, 1, 2, 3mo postoperative. Group 1 received 0.1% nepafenac (nevanac, Alcon company). In pre-operative day, three times, in operative day, one hour before surgery every 15min. In postoperative, three times daily for one month. Group 2 did not receive nepafenac.

**Phacoemulsification** Phacoemulsification was done using stop and chop technique with intra-bagel posterior chamber foldable IOL implantation. All cataract surgeries were done by the same surgeon.

**Before Phacoemulsification** Pupil were dilated with (phenylephrine 2.5% + tropicamide 1% + cyclopentolate 1%). Peribulbar anesthesia was done by using Mebevacaine HCL 3%. Sterilization of the skin was done with 10% povidene iodine and eyes were sterilized with povidene iodine 5%.

**After Phacoemulsification** Steroid-antibiotic drops 4 times daily for 2wk and then steroid was tapered over the next 3wk.

**Optical Coherence Tomography** OCT is a noninvasive and noncontact diagnostic tool with high resolution to assess macular changes. Spectral-domain OCT scan of the macula was recorded using Topcon 3D 1000 OCT. After the patient scanning was finished, analysis protocol was used to obtain circular maps on the fovea. The macular retinal map divides the region into a central area with a radius of 500 microns, and two concentric rings inner perifoveal ring and outer parafoveal ring which were divided into four quadrants.

**Multi-focal Electretinogram** MF-ERG is topographic map that records responses from central 30° the retina. This objective measurement was introduced because full-field electretinography records mass responses from the whole retina. Were recorded using Roland Consult, Brandenburg, Germany system were performed in accordance to ISCEV guidelines.

**RESULTS**

The study included 100 eyes of 100 diabetic patients with senile immature cataract. It included two groups. The demographic features presented in Table 1. The best corrected visual acuity (BCVA) was statistically insignificant between two groups at preoperative and improved significantly at first week in two groups. There were no significant differences between two groups at the first two months. But, there was a statistically significant difference at three months postoperatively ($P<0.05$; Table 2).

Central macular thickness measured by OCT was statistically insignificant between two groups post-operative. There was increase in macular thickness post-operative in Group 2 as compared to Group 1 (Table 3).

Five (5 eyes) of 50 eyes (10.0%) in Group 2 had macular edema $\geq 40 \mu m$ and no cases of edema observed in Group 1 (Figures 1, 2).

There was increase in macular thickness (more than 30 µm and less than 40 µm) in 10 eyes (20%) in Group 1 and in 25 eyes (50%) in Group 2.

There were reduction of amplitude and delay in latencies in both groups. There were statistically insignificant differences between two groups. There was improvement of MF-ERG parameters postoperative. In early post-operative (first week and first month), there were increase in amplitude and reduction of latencies. There were insignificant differences.
between the two groups in the first two months. At third month, there were significant differences between two groups; there were reduction in amplitude and delay in latencies in Group 2 than in Group 1 (Table 4).

In cases developed CMO, there were marked reduction of amplitude and delay in latencies (Figures 3, 4).

There was significant correlation between macular thickness and BCVA A in third month postoperative in Group 1 ($R$=0.5, $P$=0.005, $R$=0.6, $P$=0.004).

There was insignificant correlation between MF-ERG parameters and macular thickness (Table 5) except in five cases that developed CMO. There was significant correlation between MF-ERG amplitude and latencies and OCT macular
thickness ($R=0.55$, $P=0.005$, $R=0.52$, $P=0.004$) respectively. There was moderate increase in macular thickness with reduction in amplitude and increase in latencies (Table 5).

In Group 1 in our study, there is no case developed any complication related to nepafenac as: prolonged bleeding time, keratitis, epithelial breakdown, delayed wound healing or hypersensitivity.

**DISCUSSION**

Sub-clinical CMO is diagnosed as leakage from perifoveal dilated capillaries with fluorescein angiography without visual acuity affection after uncomplicated phacoemulsification in healthy individuals the incidence of sub-clinical CMO was less than 20%[1]. Clinical CMO can be identified on bio-

<table>
<thead>
<tr>
<th>MF-ERG</th>
<th>Preoperative</th>
<th>1st week</th>
<th>1st month</th>
<th>2nd month</th>
<th>3rd month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amplitude</td>
<td>$P$</td>
<td>0.8</td>
<td>0.06</td>
<td>0.1</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>$R$</td>
<td>-0.35</td>
<td>-0.25</td>
<td>-0.45</td>
<td>-0.41</td>
</tr>
<tr>
<td>Implicit time</td>
<td>$P$</td>
<td>0.1</td>
<td>0.2</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>$R$</td>
<td>0.25</td>
<td>0.15</td>
<td>0.35</td>
<td>0.34</td>
</tr>
</tbody>
</table>
microscopic examination and is associated with decreased visual acuity. After phacoemulsification surgery clinical CME has been reported to be less than 3% in healthy patients[12]. This study evaluated the value of addition of perioperative topical nepafenac to standard regimen of topical corticosteroids after uncomplicated phacoemulsification on central macular thickness, and retinal function in diabetic patient without diabetic changes. The study was performed on diabetic cataractous eyes because diabetes is risk factor for occurrence of CMO after cataract extraction in eyes with and without diabetic retinopathy[13]. In this study, there were five eyes (10%) developed clinical CMO (increase central macular thickness >40 µm from preoperative baseline) in Group 2 (did not receive nepafenac) in contrast to Group 1 (received perioperative nepafenac). There was no eye develop CMO in Group 1. Wittppen et al[14] was reported occurrence of CMO in only 1.8% in control group after uncomplicated phacoemulsification surgery. This is much lower than reported in this study (10%). The cause of low incidence of CMO in Wittppen et al’s study[14] was he evaluated the occurrence of CMO in low risk eyes for only one month while in this study we study the occurrence of CMO in high risk eyes (diabetic eyes) and for three months follow up. While, Singh et al[15] reported macular thickening more than 30 µm in 16.7% of patients in control group versus 2.4% in nepafenac group. He demonstrated the effect of nepafenac on 263 non-proliferative diabetic retinopathy patients began one day preoperatively and was continued for 90d follow up.

Also, Wolf et al[16] reported a significantly higher incidence of visually significant pseudophakic macular edema in patients treated with topical prednisolone alone after uneventful cataract surgery than those treated with topical prednisolone and nepafenac. Similarly, Kessel et al[17] found that the prevalence of postoperative CME was significantly higher in the steroid group than in the NSAIDs group: 25.3% versus 3.8% of patients. This study recommends using topical NSAIDs to prevent inflammation and macular edema after routine cataract surgery. That study was differ from our study as he exclude high risk patients.

Also, Tzelikis et al[18] concluded that nepafenac 0.3% was better in reducing macular thickness than placebo 5wk postoperatively without a difference in vision. Singh et al[19] reported that nepafenac 0.1% is effective in reducing postoperative CME and improvement of vision after cataract operation in diabetic patients. Yüksel et al[20] found that once-daily of nepafenac 0.3% may improve postoperative CMO in patients with high risk. Alnagdy et al[21] observed that preoperative and postoperative non-steroid anti-inflammatory reduce the frequency and severity of CME in diabetic eyes following phacoemulsification. Acar et al[22] reported that ketorolac and nepafenac decreased PGs level in both the aqueous and vitreous humors of rabbits. But, nepafenac was more effective than ketorolac in the vitreous.

In contrast, Tzelikis et al[23] reported that use of prophylactic ketorolac or nepafenac was not effective in prevention of macular thickening after uneventful cataract surgery compared with placebo. A database study of about 81 thousand eyes from patients with diabetes documented that increase risk of postoperative macular edema after surgery even in absence of diabetic retinopathy[24].

Also, multicenter database study across 19 centers from an electronic medical record system including 4850 eyes undergoing cataract surgery in patients with diabetes with no history of diabetic macular edema (DMO) demonstrated increase the rate of DMO that requiring treatment for one year postoperative. Risk of treatment-requiring DMO differed according to preoperative grade of retinopathy: being 1.0% in diabetic patients without diabetic retinopathy, 5.4% in mild non-proliferative diabetic retinopathy (NPDR), 10.0% in moderate NPDR, 13.1% in severe NPDR and 4.9% in proliferative diabetic retinopathy[25].

In contrast to this database, this study documented increase risk of treatment requiring CME to 10%. Our study was of limited number and diabetic patients were without diabetic retinopathy. Hayashi et al[21] found that, the degree of changes of DMO is more prominent in eyes with DR than in eyes without DR. Macular edema increases up to 3mo after cataract surgery, but thereafter decreases gradually.

In the present study all cases had no diabetic retinopathy preoperatively and macular thickening was reported postoperatively statistically significant in Group 2 than Group 1. There were reduction in amplitude with delay in latencies in both groups preoperatively due to lens opacity and diabetes. There were improvement of latencies and increase in amplitude postoperative in both groups due to removal of cataract. There were insignificant differences between both groups in the first two months. There was marked reduction of amplitude with increase in latency in Group 2 in cases of CMO.

Also, Bearse et al[26] found delay in latencies with and without reduction in amplitude in diabetes even in eyes without diabetic retinopathy. Gerth et al[27] reported reduction in MF-ERG values in opaque media due to reduction in illumination reached retina.

ACKNOWLEDGEMENTS

Conflicts of Interest: Mokbel T, None; Saleh S, None; Abdelkader M, None; El-khously SE, None; Abou Samra W, None; Mamdouh M, None.
REFERENCES


7 Bucci FA Jr, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevaneac) in patients undergoing phacoemulsification. *Am J Ophthalmol* 2007;144(1):146-147.


18 Tzelikis PF, Morato CS, Neves NT, Hida WT, Alves MR. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification. *J Cataract Refract Surg* 2018;44(4):440-446.


22 Acar U, Acar DE, Tanriverdi C, Acar M, Ozdemir O, Eriksø A, Oren F. Prostaglandin E2 levels of aqueous and vitreous humor in ketorolac 0.4% and nepafenac 0.1% administered healthy rabbits. *Ocul Immunol Inflamm* 2017;25(3):323-327.


